Vimarsana
Biggest News Aggregation in the World

Page 16 - Priya Singhal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Priya Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Priya Singhal Today - Breaking & Trending Today

Biogen's positive step for ALS and neuromuscular disease patients - Vimarsana News

Biogen's positive step for ALS and neuromuscular disease patients

Biogen Inc. has announced a significant advancement in the treatment of amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease (MND).

Biogen (NASDAQ:BIIB) Price Target Cut to $305.00 - Vimarsana News

Biogen (NASDAQ:BIIB) Price Target Cut to $305.00

Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by Canaccord Genuity Group from $310.00 to $305.00 in a research note published on Tuesday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock. Several other research firms have also commented on BIIB. Robert W. Baird reduced their price […]

Profund Advisors LLC Boosts Position in Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

Profund Advisors LLC Boosts Position in Biogen Inc. (NASDAQ:BIIB)

Profund Advisors LLC grew its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 26.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 17,041 shares of the biotechnology company’s stock after purchasing an additional 3,584 shares during the quarter. Profund Advisors LLC’s holdings in Biogen were worth $4,380,000 as of its most recent SEC […]

Biogen's (BIIB) "Overweight" Rating Reiterated at Cantor Fitzgerald - Vimarsana News

Biogen's (BIIB) "Overweight" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note released on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $311.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on BIIB. Wells Fargo & Company cut Biogen from […]

Biogen's QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP -February 23, 2024 at 07:01 am EST - Vimarsana News

Biogen's QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP -February 23, 2024 at 07:01 am EST

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development...